In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels.

Published on May 19, 2021in Nature Biotechnology36.558
· DOI :10.1038/S41587-021-00933-4
Tanja Rothgangl1
Estimated H-index: 1
(UZH: University of Zurich),
Melissa K. Dennis1
Estimated H-index: 1
+ 29 AuthorsGerald Schwank18
Estimated H-index: 18
(UZH: University of Zurich)
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and safety of ABEs in the livers of mice and cynomolgus macaques for the reduction of blood low-density lipoprotein (LDL) levels. Lipid nanoparticle-based delivery of mRNA encoding an ABE and a single-guide RNA targeting PCSK9, a negative regulator of LDL, induced up to 67% editing (on average, 61%) in mice and up to 34% editing (on average, 26%) in macaques. Plasma PCSK9 and LDL levels were stably reduced by 95% and 58% in mice and by 32% and 14% in macaques, respectively. ABE mRNA was cleared rapidly, and no off-target mutations in genomic DNA were found. Re-dosing in macaques did not increase editing, possibly owing to the detected humoral immune response to ABE upon treatment. These findings support further investigation of ABEs to treat patients with monogenic liver diseases.
📖 Papers frequently viewed together
42 Authors (Kiran Musunuru, ..., Sekar Kathiresan)
16 Citations
71 Citations
#1Lukas Villiger (ETH Zurich)H-Index: 4
#2Tanja Rothgangl (ETH Zurich)H-Index: 1
Last. Gerald Schwank (ETH Zurich)H-Index: 18
view all 17 authors...
Base editors are RNA-programmable deaminases that enable precise single-base conversions in genomic DNA. However, off-target activity is a concern in the potential use of base editors to treat genetic diseases. Here, we report unbiased analyses of transcriptome-wide and genome-wide off-target modifications effected by cytidine base editors in the liver of mice with phenylketonuria. The intravenous delivery of intein-split cytidine base editors by dual adeno-associated viruses led to the repair o...
4 CitationsSource
#1Mandana Arbab (Broad Institute)H-Index: 6
#2Max W. ShenH-Index: 8
Last. David R. Liu (Broad Institute)H-Index: 100
view all 7 authors...
Summary Although base editors are widely used to install targeted point mutations, the factors that determine base editing outcomes are not well understood. We characterized sequence-activity relationships of 11 cytosine and adenine base editors (CBEs and ABEs) on 38,538 genomically integrated targets in mammalian cells and used the resulting outcomes to train BE-Hive, a machine learning model that accurately predicts base editing genotypic outcomes (R ≈ 0.9) and efficiency (R ≈ 0.7). We correct...
41 CitationsSource
#1Alec W. Freyn (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Jamile Ramos da Silva (USP: University of São Paulo)H-Index: 1
Last. Raffael Nachbagauer (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 26
view all 15 authors...
Abstract Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle encapsulated, nucleoside-mo...
27 CitationsSource
#1Kim F Marquart (UZH: University of Zurich)H-Index: 1
#1Kim Marquart (UZH: University of Zurich)H-Index: 1
Last. Gerald Schwank (UZH: University of Zurich)H-Index: 18
view all 8 authors...
Base editors are chimeric ribonucleoprotein complexes consisting of a DNA-targeting CRISPR-Cas module and a single-stranded DNA deaminase. They enable conversion of C-G into T-A base pairs and vice versa on genomic DNA. While base editors have vast potential as genome editing tools for basic research and gene therapy, their application has been hampered by a broad variation in editing efficiencies on different genomic loci. Here we perform an extensive analysis of adenine- and cytosine base edit...
5 CitationsSource
#1Andrew V. Anzalone (Broad Institute)H-Index: 10
#1Andrew V. Anzalone (Broad Institute)H-Index: 1
Last. David R. Liu (Broad Institute)H-Index: 100
view all 3 authors...
The development of new CRISPR–Cas genome editing tools continues to drive major advances in the life sciences. Four classes of CRISPR–Cas-derived genome editing agents—nucleases, base editors, transposases/recombinases and prime editors—are currently available for modifying genomes in experimental systems. Some of these agents have also moved rapidly into the clinic. Each tool comes with its own capabilities and limitations, and major efforts have broadened their editing capabilities, expanded t...
245 CitationsSource
#1Cicera R. Lazzarotto (St. Jude Children's Research Hospital)H-Index: 6
#1Cicera R. Lazzarotto (St. Jude Children's Research Hospital)H-Index: 6
Last. Shengdar Q. Tsai (St. Jude Children's Research Hospital)H-Index: 27
view all 20 authors...
Current methods can illuminate the genome-wide activity of CRISPR–Cas9 nucleases, but are not easily scalable to the throughput needed to fully understand the principles that govern Cas9 specificity. Here we describe ‘circularization for high-throughput analysis of nuclease genome-wide effects by sequencing’ (CHANGE-seq), a scalable, automatable tagmentation-based method for measuring the genome-wide activity of Cas9 in vitro. We applied CHANGE-seq to 110 single guide RNA targets across 13 thera...
27 CitationsSource
#1Wei-Hsi Yeh (Broad Institute)H-Index: 7
#2Olga Shubina-Oleinik (Boston Children's Hospital)H-Index: 4
Last. David R. Liu (Broad Institute)H-Index: 100
view all 10 authors...
Most genetic diseases arise from recessive point mutations that require correction, rather than disruption, of the pathogenic allele to benefit patients. Base editing has the potential to directly repair point mutations and provide therapeutic restoration of gene function. Mutations of transmembrane channel-like 1 gene (TMC1) can cause dominant or recessive deafness. We developed a base editing strategy to treat Baringo mice, which carry a recessive, loss-of-function point mutation (c.A545G; res...
30 CitationsSource
#1Mitchell G. Kluesner (UMN: University of Minnesota)H-Index: 5
#2Walker S. Lahr (UMN: University of Minnesota)H-Index: 5
Last. Branden S. Moriarity (UMN: University of Minnesota)H-Index: 24
view all 12 authors...
Base editors allow for precise nucleotide editing without the need for genotoxic double-stranded breaks. Prior work has used base editors to knockout genes by introducing premature stop codons or by disrupting conserved splice-sites, but no direct comparison exists between these methods. Additionally, while base editor mediated disruption of splice sites has been used to shift the functional isoform pool, its utility for gene knockout requires further validation. To address these needs, we devel...
4 CitationsSource
#1Gaudelli NicoleH-Index: 5
#2Dieter K. LamH-Index: 2
Last. Giuseppe CiaramellaH-Index: 3
view all 17 authors...
The foundational adenine base editors (for example, ABE7.10) enable programmable A•T to G•C point mutations but editing efficiencies can be low at challenging loci in primary human cells. Here we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s. At NGG protospacer adjacent motif (PAM) sites, ABE8s result in ~1.5× higher editing at protospacer positions A5–A7 and ~3.2× higher editing at positions A3–A4 and A8–A10 compared with ABE7.10. Non-NGG PAM variants ha...
68 CitationsSource
#1Michelle F. Richter (Broad Institute)H-Index: 4
#2Kevin T. Zhao (Broad Institute)H-Index: 7
Last. David R. Liu (Broad Institute)H-Index: 100
view all 12 authors...
Applications of adenine base editors (ABEs) have been constrained by the limited compatibility of the deoxyadenosine deaminase component with Cas homologs other than SpCas9. We evolved the deaminase component of ABE7.10 using phage-assisted non-continuous and continuous evolution (PANCE and PACE), which resulted in ABE8e. ABE8e contains eight additional mutations that increase activity (kapp) 590-fold compared with that of ABE7.10. ABE8e offers substantially improved editing efficiencies when pa...
89 CitationsSource
Cited By8
#1Coen C. Paulusma (UvA: University of Amsterdam)H-Index: 25
#2Piter J. Bosma (UvA: University of Amsterdam)H-Index: 36
Gene editing to correct inherited liver disorders has promise for future therapeutic intervention, but lack of effective and safe delivery of the gene-editing machinery to hepatocytes complicates its clinical application. Two studies now report efficient delivery to the liver of non-human primates, providing proof of concept for novel treatment of inherited hypercholesterolaemia.
#1Francesco Paneni (UZH: University of Zurich)H-Index: 31
#2Massimo Volpe (Sapienza University of Rome)H-Index: 89
#1Desiree Boeck (UZH: University of Zurich)
#2Tanja Rothgangl (UZH: University of Zurich)H-Index: 1
Last. Hiu Man Grisch-ChanH-Index: 7
view all 0 authors...
Prime editing is a highly versatile CRISPR-based genome editing technology with the potential to correct the vast majority of pathogenic mutations (1). However, correction of a disease phenotype in vivo in somatic tissues has not been demonstrated thus far. Here, we establish proof-of-concept for in vivo prime editing and repair the metabolic liver disease phenylketonuria (PKU) in mice. We first developed a size-reduced SpCas9 prime editor (PE) lacking the RNaseH domain of the reverse transcript...
#1Andrew J. Murphy (Baker IDI Heart and Diabetes Institute)H-Index: 94
#2Mark A. Febbraio (Monash University)H-Index: 111
Cardiometabolic disorders were originally thought to be driven primarily by changes in lipid metabolism that cause the accumulation of lipids in organs, thereby impairing their function. Thus, in the setting of cardiovascular disease, statins - a class of lipid-lowering drugs - have remained the frontline therapy. In the past 20 years, seminal discoveries have revealed a central role of both the innate and adaptive immune system in driving cardiometabolic disorders. As such, it is now appreciate...
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is secreted mostly by hepatocytes and to a lesser extent by the intestine, pancreas, kidney, adipose tissue, and vascular cells. PCSK9 has been known to interact with the low-density lipoprotein receptor (LDLR) and chaperones the receptor to its degradation. In this manner, targeting PCSK9 is a novel attractive approach to reduce hyperlipidaemia and the risk for cardiovascular diseases. Recently, it has been recognised that the effects of PC...
#1Sebastiaan Johannes van Kampen (UU: Utrecht University)H-Index: 2
#2Eva van Rooij (UU: Utrecht University)H-Index: 49
PCSK9 inhibitors are a class of cholesterol-lowering drugs that regulate LDL-receptor degradation. Three new studies show successful reduction of PCSK9 levels by different approaches that all resulted in the lowering of LDL-cholesterol levels.
It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described. It was soon clear that this protein would have been of huge scientific and clinical value as a therapeutic strategy for dyslipidemia and atherosclerosis-associated cardiovascular disease (CVD) management. Indeed, PCSK9 is a serine protease belonging to the proprotein convertase family, mai...
1 CitationsSource
Two studies report the successful application of CRISPR adenine base editors for in vivo genome editing of a disease-related gene in non-human primates.